liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Dreimane, Arta
Publications (5 of 5) Show all publications
Gunnarsson, N., Höglund, M., Stenke, L., Wallberg-Jonsson, S., Sandin, F., Björkholm, M., . . . Sjalander, A. (2016). Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia. Leukemia, 30(7), 1562-1567
Open this publication in new window or tab >>Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia
Show others...
2016 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 30, no 7, p. 1562-1567Article in journal (Refereed) Published
Abstract [en]

We recently reported an increased incidence of second malignancies in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI). To elucidate whether this increase may be linked, not to TKI but rather to a hereditary or acquired susceptibility to develop cancer, we estimated the prevalence of malignancies, autoimmune disease (AD) and chronic inflammatory disease (CID) in CML patients prior to their CML diagnosis. Nationwide population-based registers were used to identify patients diagnosed with CML in Sweden 2002-2012 and to estimate the prevalence of other malignancies, AD and CID prior to their CML diagnosis. For each patient with CML, five matched controls were selected from the general population. Conditional logistic regression was used to calculate odds ratios (OR). Nine hundred and eighty-four CML patients were assessed, representing more than 45 000 person-years of follow-up. Compared with matched controls, the prevalence of prior malignancies and AD was elevated in CML patients: OR 1.47 (95% confidence interval (CI) 1.20-1.82) and 1.55 (95% CI 1.21-1.98), respectively. No associations were detected between CML and previous CID. An increased prevalence of other malignancies and AD prior to the diagnosis of CML suggest that a hereditary or acquired predisposition to cancer and/or autoimmunity is involved in the pathogenesis of CML.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP, 2016
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-130408 (URN)10.1038/leu.2016.59 (DOI)000379504400013 ()27080811 (PubMedID)
Note

Funding Agencies|Emil Andersson Research Fund; Nordic CML Study Group

Available from: 2016-08-15 Created: 2016-08-05 Last updated: 2017-04-24
Hjorth-Hansen, H., Stenke, L., Söderlund, S., Dreimane, A., Ehrencrona, H., Gedde-Dahl, T., . . . Richter, J. (2015). Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). European Journal of Haematology, 94(3), 243-250
Open this publication in new window or tab >>Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
Show others...
2015 (English)In: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 94, no 3, p. 243-250Article in journal (Refereed) Published
Abstract [en]

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100mg QD or imatinib 400mg QD and report outcome as an intention-to-treat analysis with 36months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group, with a tendency that imatinib patients caught up with time. For instance, MR3.0 was reached at 3months in 36% vs. 8% (P=0.02), at 12months in 81% vs. 46% (P=0.02) and at 18months in 73% vs. 65% (n.s.) of the patients in the two groups. In contrast, MR4.5 was consistently superior in the dasatinib group at all time points from 6months onwards, reaching 61% vs. 21% (Pless than0.05) at 36months. Sixty-four vs. 71% of the patients in the dasatinib and imatinib arms, respectively, remained on assigned drug. Dasatinib dose was frequently reduced, but with maintained excellent effect. One imatinib patient progressed to blastic phase, but no CML-related deaths occurred. In conclusion, our data compare favourably with those of the dasatinib registration study, DASISION. The fast and deep molecular responses induced by dasatinib compared with imatinib may be exploited to increase the proportion of patients who can achieve a treatment-free remission after treatment discontinuation.

Place, publisher, year, edition, pages
Wiley: 12 months, 2015
Keywords
dasatinib; imatinib; randomized controlled trial; deep response; toxicity
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-116957 (URN)10.1111/ejh.12423 (DOI)000350357900008 ()25082346 (PubMedID)
Note

Funding Agencies|Bristol-Myers Squibb

Available from: 2015-04-10 Created: 2015-04-10 Last updated: 2017-12-04
Gunnarsson, N., Stenke, L., Hoglund, M., Sandin, F., Bjorkholm, M., Dreimane, A., . . . Sjalander, A. (2015). Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. British Journal of Haematology, 169(5), 683-688
Open this publication in new window or tab >>Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
Show others...
2015 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 169, no 5, p. 683-688Article in journal (Refereed) Published
Abstract [en]

Given that tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with chronic myeloid leukaemia (CML), we were interested in examining the possible risk of long-term adverse events, such as the emergence of other neoplasms. Therefore, we studied the development of second malignancies in 868 patients diagnosed with CML between 2002 and 2011 using the Swedish CML register, cross-linked to the Swedish Cancer register. With a median follow-up of 37 (range 0-99)years, 65 (75%) patients developed 75 second malignancies (non-haematological), 52 of which were of the invasive type. Compared to expected rates in the background population, the risk of second malignancies was higher in the CML cohort, with a standardized incidence ratio (SIR) of 152 (95% CI 113-199). The SIR before and after the second year following diagnosis of CML was 158 and 147, respectively. Among specific cancer types, gastrointestinal and nose and throat cancer were significantly increased. Founded on a population-based material, our results indicate that CML patients treated in the TKI era are at an increased risk of developing a second malignancy, with indications that this risk may more likely be linked to CML itself rather than to the TKI treatment.

Place, publisher, year, edition, pages
Wiley, 2015
Keywords
chronic myeloid leukaemia; treatment; malignancy
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-119236 (URN)10.1111/bjh.13346 (DOI)000354489800009 ()25817799 (PubMedID)
Note

Funding Agencies|Emil Andersson Research Fund

Available from: 2015-06-15 Created: 2015-06-12 Last updated: 2017-12-04
Richter, J., Soderlund, S., Lubking, A., Dreimane, A., Lotfi, K., Markevarm, B., . . . Stenke, L. (2014). Letter: Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome? in JOURNAL OF CLINICAL ONCOLOGY, vol 32, issue 25, pp 2821-2823 [Letter to the editor]. Journal of Clinical Oncology, 32(25), 2821-2823
Open this publication in new window or tab >>Letter: Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome? in JOURNAL OF CLINICAL ONCOLOGY, vol 32, issue 25, pp 2821-2823
Show others...
2014 (English)In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 25, p. 2821-2823Article in journal, Letter (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
American Society of Clinical Oncology: JCO, 2014
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-111276 (URN)10.1200/JCO.2014.55.6910 (DOI)000341562600033 ()25071107 (PubMedID)
Available from: 2014-10-14 Created: 2014-10-14 Last updated: 2017-12-05
Hoglund, M., Sandin, F., Hellstrom, K., Bjoreman, M., Bjorkholm, M., Brune, M., . . . Richter, J. (2013). Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood, 122(7), 1284-1292
Open this publication in new window or tab >>Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
Show others...
2013 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 122, no 7, p. 1284-1292Article in journal (Refereed) Published
Abstract [en]

Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100 000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (andlt;70 years) and 79% for older (andgt;80 years) patients during 2007-2009. With a median follow-up of 61 months, the relative survival at 5 years was close to 1.0 for patients younger than 60 years and 0.9 for those aged 60 to 80 years, but only 0.6 for those older than 80 years. At 12 months, 3% had progressed to accelerated or blastic phase. Sokal, but not European Treatment and Outcome Study, high-risk scores were significantly linked to inferior overall and relative survival. Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival.

Place, publisher, year, edition, pages
American Society of Hematology, 2013
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-97664 (URN)10.1182/blood-2013-04-495598 (DOI)000323392900028 ()
Note

Funding Agencies|Novartis||

Available from: 2013-09-19 Created: 2013-09-19 Last updated: 2017-12-06
Organisations

Search in DiVA

Show all publications